Home
Clinical Trials
Safety and Immunological Resp...

Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients

Last Updated: 2008-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2002-08-31

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the immunological response rate to administration of the THERATOPE® vaccine in women with stable metastatic breast cancer who are being treated with aromatase inhibitors or Faslodex® and who do not require chemotherapy.

Post-menopausal women on aromatase inhibitors or Faslodex® alone and pre-menopausal women on aromatase inhibitors plus luteinising hormone-releasing hormone (LH/RH)-agonist may be eligible to be enrolled.

Patients must not have had radiotherapy or major surgery within four (4) weeks prior to entering the study.

Information about the safety and tolerability of administration of the THERATOPE® vaccine will also be gathered during the course of the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

NCT00003638

Breast Cancer

COMPLETED PHASE3

Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer

NCT00107393

Breast Cancer

COMPLETED PHASE2

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

NCT05955170

HER2-positive Breast Cancer

RECRUITING PHASE2

Thero2-01S22 in HER2-positive Breast Cancer

NCT05698186

HER2-positive Breast Cancer

NOT_YET_RECRUITING PHASE3

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

NCT00971737

Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

THERATOPE® vaccine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histopathologically confirmed breast cancer
* Documented Stage IV disease
* Estrogen and/or progesterone-receptor positive
* Stable disease on aromatase inhibitor or Faslodex® treatment begun at least 12 weeks prior to enrolment
* Performance status, ECOG = 0 or 1
* Life expectancy \> 12 weeks
* History of freedom from progression for at least 6 months following surgery with a curative intent or for at least 6 months during adjuvant chemotherapy, adjuvant radiotherapy or adjuvant hormonal therapy such as tamoxifen/toremifene treatment
* No radiotherapy or major surgery within 4 weeks prior to enrolment

Exclusion Criteria

* Pregnant or lactating
* Known brain metastasis
* Bone marrow involvement as the only site of metastasis
* First line chemotherapy for Stage IV disease
* Past or current cancer other than breast cancer, except for curatively treated basal cell cancer or in situ cancer of the cervix with no evidence of disease
* Autoimmune disease, e. g., type I juvenile onset diabetes mellitus, antibody positive rheumatoid arthritis, Grave's disease, lupus, Crohn's disease, IBD, Hashimoto's thyroiditis
* Known intercurrent infections (including HBV or HCV) or immunosuppression \[human immunodeficiency virus (HIV) or other conditions\] or clinical evidence of these conditions
* Other significant active infection
* Pleural effusions and/or ascites requiring paracentesis every 2 weeks or more frequently
* Splenectomy
* Concurrent treatment with chemotherapeutic agents other than low-dose cyclophosphamide used in this study
* Treatment with interferons (IFNs), cytokines, systemic steroids or other biologicals within 4 weeks prior to enrolment
* Receipt of another investigational drug within 30 days of enrolment
* Known allergy to shellfish
* Known allergy to soy beans or soy products
* Known hypersensitivity to polysorbate 80
* Known hypersensitivity to the study drugs
* Legal incapacity or limited legal capacity

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers